Predicted off-label usages binned by risk and cost and ranked by support in FAERS.

We ranked predicted, novel off-label usages on the basis of risk and cost, as represented by our risk and cost indices for each drug. FAERS Support for each drug-indication pair is the number of distinct case reports in FAERS in which the drug was explicitly listed as being used to treat the indication. The risk index is a quantitative score that represents the expected disutility of adverse events related to the use of the drug in question, normalized to the range [0, 1] so that drugs that have a higher risk of causing serious adverse events have higher values. The cost index is based on the mean unit cost of the drug in question in Medi-Span, normalized to the range [0, 1] with more expensive drugs having a higher value.